Influence of glycemic control on gain in VO2 peak, in patients with type 2 diabetes enrolled in cardiac rehabilitation after an acute coronary syndrome. The prospective DARE study

Table 4 Multivariable analysis with gain in VO2peak as dependent variable

Variables	β	t	p
A. Model 1 with age, gender, duration of diabetes, BMI, baseline fructosamine, final fructosamine, baseline VO2 peak, type of SCA and treatment group (insulin intensive/control) as independent variables
Final fructosamine	−0.357	−2.680	0.010
Age	−0.086	−0.638	0.527
Gender	−0.090	−0.638	0.527
Diabetes duration	−0.033	−0.240	0.812
BMI	−0.092	−0.651	0.518
Baseline fructosamine	−0.167	−1.032	0.307
Baseline VO2 peak	0.123	0.920	0.362
Type of ACS	−0.106	−0.786	0.436
Treatment group (insulin intensive/control)	−0.038	−0.282	0.779
B. Model 2 (similar to model 1 with the variable “Fructosamine above the median” instead of “Final fructosamine”)
Fructosamine above median	−0.342	−2.549	0.014
Age	−0.077	−0.572	0.570
Gender	−0.099	−0.695	0.490
Diabetes duration	−0.040	−0.295	0.769
BMI	−0.083	−0.588	0.559
Baseline fructosamine	−0.207	−1.406	0.166
Baseline VO2 peak	0.099	0.736	0.465
Type of ACS	−0.184	−1.379	0.174
treatment group (insulin intensive/control)	−0.046	−0.338	0.737

β standardized coefficient
ACS acute coronary syndrome
Similar results when the variable “Treatment with insulin” is introduced into the model instead of “Treatment group (insulin intensive/control)”

ISSN: 1471-2261